肾结石病和钠-葡萄糖协同转运蛋白-2（SGLT-2）抑制剂：随机对照试验的荟萃分析。
Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
机构信息
Diabetology, Careggi Hospital and University of Florence, Italy.
Diabetology, Careggi Hospital and University of Florence, Italy.
出版信息
Diabetes Res Clin Pract. 2019 Sep;155:107808. doi: 10.1016/j.diabres.2019.107808. Epub 2019 Aug 8.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) decreased serum uric acid in type 2 diabetes. Hyperuricemia is associated with an increased risk of nephrolithiasis. The present meta-analysis, performed on trials with duration ≥52 weeks in comparison with placebo or active comparators, suggests no effects of SGLT-2i on the risk of nephrolithiasis.
摘要
钠-葡萄糖共转运蛋白 2 抑制剂 (SGLT2i) 可降低 2 型糖尿病患者的血清尿酸水平。高尿酸血症与肾结石风险增加相关。本荟萃分析对持续时间≥52 周的试验进行了研究，与安慰剂或活性对照药物相比，提示 SGLT-2i 对肾结石风险无影响。
Zotero 插件